The year 2025 has been marked by turbulence in the U.S. healthcare stock market, with investors witnessing significant dips across biotechnology, insurance, and pharmaceutical equities. Yet, amid this turmoil, Fildena and other erectile dysfunction (ED) medications stand out as resilient performers. While broader pharmaceutical shares struggle, ED drugs are demonstrating remarkable stability,...

In 2025, the fusion of wearable technology and personal health decision-making has reshaped the healthcare landscape in the United States. As consumers seek autonomy in managing chronic conditions, preventive care, and alternative therapies, self-medication with drugs like Ivermectin has become a trending topic—particularly when paired with the use of wearable tech for health tracking....